5,748 results match your criteria Annales D Endocrinologie[Journal]


Women's cardiovascular risk before and after menopause: A red alert for heart attack!

Ann Endocrinol (Paris) 2020 Mar 5. Epub 2020 Mar 5.

CHU Lille, Institut Cœur Poumon, Médecine Vasculaire et HTA, 59000 Lille, France; Université Lille, EA 2694 - Santé Publique: Epidémiologie et Qualité des Soins, 59000 Lille, France. Electronic address:

Cardiovascular disease is now the leading cause of death in women, 16 times more frequent than breast cancer, and with more and more young women at risk. Young women are exposed to serial loss of chance, related to sex, with specific female hormonal cardiovascular risk factors (CVRF): contraception, pregnancy and menopause; and to gender: atypic symptoms, underestimation, poor risk-factor control, undertreatment and lack of follow-up, and specific atheromatous disease. Prevalence and impact of risk factors differ between males and females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.006DOI Listing

Cardiac complications of thyroid hormone resistance syndromes.

Ann Endocrinol (Paris) 2020 Jun 5. Epub 2020 Jun 5.

Département d'EDN, Centre de Référence de la Thyroide et des Récepteurs Hormonaux, CHU Angers, 49933 Angers, France; Institut MITOVASC, Université d'Angers, 49000 Angers, France.

Thyroid hormones exert their action by binding to their thyroid hormone receptors among other mechanisms. They are involved in different cardiac functions, including contractility and rhythm. The mutation of thyroid hormone receptor β is the main cause of thyroid hormone resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.008DOI Listing

Investigating cardiac β-adrenergic nuclear signaling with FRET-based biosensors.

Ann Endocrinol (Paris) 2020 Apr 7. Epub 2020 Apr 7.

Inserm, signaling and cardiovascular pathophysiology, UMR-S1180, université Paris-Saclay, 92296 Châtenay-Malabry, France.

By activating membrane β-adrenergic receptors (β-AR), noradrenaline and adrenaline are the most powerful stimulators of cardiac function. β-ARs are coupled to the synthesis of cAMP, which activates the cAMP-dependent protein kinase (PKA). PKA regulates the key proteins of excitation-contraction coupling but also gene expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.001DOI Listing

Aldosterone receptor antagonists.

Authors:
Michel Azizi

Ann Endocrinol (Paris) 2020 May 27. Epub 2020 May 27.

Inserm CIC1418, service d'hypertension artérielle et DMU CARTE, HEGP, université de Paris, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. Electronic address:

Blocking the mineralocorticoid receptor (MR) is one of the most effective ways of reducing blood pressure in patients with resistant hypertension and improving cardiovascular prognosis in patients with heart failure with reduced ejection fraction and left ventricular dysfunction after myocardial infarction. Blockade of the biological effects of aldosterone has mostly been achieved with spironolactone and eplerenone, the two steroidal MR antagonists currently on the market. Development of new non-steroidal dihydropyridine-based third- and fourth-generation MR antagonists is ongoing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.009DOI Listing

Adrenergic receptors and cardiovascular effects of catecholamines.

Ann Endocrinol (Paris) 2020 Mar 18. Epub 2020 Mar 18.

Department of Physiology, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, 75018 Paris, France; Université de Paris, Paris, France. Electronic address:

Activation of the sympathetic nervous system is responsible for the body's "fight or flight" reaction. The physiological responses to the activation of the sympathetic nervous system and adrenal medulla are mediated through the action of the endogenous catecholamines norepinephrine (or noradrenaline) and epinephrine (or adrenaline) on adrenergic receptors. Adrenergic receptors belong to the superfamily of G protein-coupled receptors (GPCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.012DOI Listing

The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH.

Authors:
Philippe Chanson

Ann Endocrinol (Paris) 2020 Mar 4. Epub 2020 Mar 4.

Service d'endocrinologie et des maladies de la reproduction, centre de référence des maladies rares de l'hypophyse, Assistance publique-hôpitaux de Paris, hôpital Bicêtre, 78, rue du Général-Leclerc, 94275, Le Kremlin-Bicêtre, France; Université Paris-Saclay, université Paris-Sud, Inserm, signalisation hormonale, physiopathologie endocrinienne et métabolique, 94276, Le Kremlin-Bicêtre, France. Electronic address:

Besides its effects on longitudinal growth in childhood and its metabolic effects with consequences on body composition and lipid levels, growth hormone (GH) has important roles on maintaining the structure and function of the normal adult heart. GH/insulin like growth factor-I (IGF-I) also interacts with the vascular system and plays a role in the regulation of vascular tone. GH deficiency (GHD) in adulthood is associated with increased fat mass (particularly visceral) and abnormal lipid profile, which may contribute to the excess cardiovascular mortality observed in patients with panhypopituitarism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.005DOI Listing

Levothyroxine dose adjustment in hypothyroid patients following gastric sleeve surgery.

Ann Endocrinol (Paris) 2020 May 20. Epub 2020 May 20.

Universitaire de Nimes, Centre Hospitalier, France.

Introduction: Euthyroid patients show decreased TSH level following sleeve gastrectomy. However, studies of levothyroxine absorption after bariatric surgery reported contradictory results and data on levothyroxine dose adjustment according to weight are sparse. The aim of this study was to evaluate levothyroxine dose adjustment during weight loss following sleeve surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.011DOI Listing

COVID-19 in diabetic patients: Related risks and specifics of management.

Ann Endocrinol (Paris) 2020 Jun 12;81(2-3):101-109. Epub 2020 May 12.

Department of internal medicine, Cliniques Universitaires Saint-Luc, avenue Hippocrate 10, 1200 Brussels, Belgium.

Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217100PMC

Clinical phenotype of mitochondrial diabetes due to rare mitochondrial DNA mutations.

Ann Endocrinol (Paris) 2020 Jun 28;81(2-3):68-77. Epub 2020 Apr 28.

Service d'endocrinologie, diabétologie et médecine de la reproduction, hôpital de l'Archet 2, université Côte d'Azur, CHU de Nice, Nice, France; Institut national de la santé et de la recherche médicale (Inserm), UMR U1065/UNS, Centre méditerranéen de médecine moléculaire (C3M), équipe 5 « Cellular Basis and Signaling of Tumor Metabolism », Université Côte d'Azur, CHU de Nice, Nice, France. Electronic address:

Objective: While the most frequent mutation responsible for mitochondrial diabetes is the point mutation m.3243 A>G of mitochondrial DNA (mtDNA), few data are available about the role of rare mtDNA mutations in the pathophysiology of diabetes. The main objective of our study was to describe the phenotypic characteristics of patients suffering from diabetes linked to rare mtDNA mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.007DOI Listing

Case report: A rare cause of severe hypophosphatemia.

Ann Endocrinol (Paris) 2020 Jun 4;81(2-3):125-126. Epub 2020 May 4.

Department of Endocrinology and Nutrition, Hospital Clínico Universitario Lozano-Blesa, 15, San-Juan-Bosco avenue, 50009 Zaragoza, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.008DOI Listing

Rare causes of hypoglycemia in adults.

Ann Endocrinol (Paris) 2020 Jun 10;81(2-3):110-117. Epub 2020 Apr 10.

Endocrinology, diabetology, metabolism department, Lille university hospital, Lille, France; Inserm U1190 translational research in diabetes, Lille, France; European genomic institute for diabetes EGID, Lille, France. Electronic address:

Hypoglycemia is defined by a low blood glucose level associated to clinical symptoms. Hypoglycemia may be related to treatment of diabetes, but also to drugs, alcohol, critical illness, cortisol insufficiency including hypopituitarism, insulinoma, bariatric or gastric surgery, pancreas transplantation or glucagon deficiency, or may be surreptitious. Some hypoglycemic episodes remain unexplained, and genetic, paraneoplastic and immune causes should be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.003DOI Listing

Amiodarone-induced thyrotoxicosis.

Ann Endocrinol (Paris) 2020 Apr 29. Epub 2020 Apr 29.

Service endocrinologie, AP-HP, hôpital Cochin, 75014 Paris, France; Université de Paris, 75014 Paris, France; Institut Cochin, Inserm Unité 1016, CNRS UMR 8104, 75014 Paris, France. Electronic address:

Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians are sometimes faced with difficult diagnostic and therapeutic situations. The disease pathophysiology is partially understood, explaining the lack of predictive factors for occurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.009DOI Listing

Multiple Endocrine Neoplasia Type 4: Novel CDNK1B variant and immune anomalies.

Ann Endocrinol (Paris) 2020 Jun 10;81(2-3):124-125. Epub 2020 Apr 10.

Endocrinology, Diabetology, Metabolism Department, Lille University Hospital1, Rue Polonovski, C. Huriez Hospital, Lille University Hospital, 59037 Lille Cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.002DOI Listing

Covid-19: The challenges facing endocrinology.

Ann Endocrinol (Paris) 2020 06 25;81(2-3):61-62. Epub 2020 Apr 25.

Endocrinology, Diabetology, Metabolism Department, Lille University Hospital, 59000 Lille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195032PMC

Renin-angiotensin-aldosterone system and COVID-19 infection.

Ann Endocrinol (Paris) 2020 Jun 21;81(2-3):63-67. Epub 2020 Apr 21.

Service d'hypertension artérielle et thérapeutique PCVM, CHU de Rangueil, UMR 1027 université Toulouse 3, 1, avenue J.-Poulhes 31059 Toulouse cedex 9, France.

With the multiplication of COVID-19 severe acute respiratory syndrome cases due to SARS-COV2, some concerns about angiotensin-converting enzyme 1 (ACE1) inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARB) have emerged. Since the ACE2 (angiotensin-converting enzyme 2) enzyme is the receptor that allows SARS COV2 entry into cells, the fear was that pre-existing treatment with ACEi or ARB might increase the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection. The present article discusses these concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172808PMC

Gonad differentiation toward ovary.

Ann Endocrinol (Paris) 2020 Jun 15;81(2-3):83-88. Epub 2020 Apr 15.

Service d'endocrinologie, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 75012 Paris, France; Sorbonne université, Paris, France; UMR 933 75012 Paris, France. Electronic address:

Gonad differentiation depends on a set of cellular and hormonal signals interacting in a specific order, with very precise windows of action, to contribute to the establishment of the genital tract and a male or female phenotype. Research initially focused on the stages of gonad differentiation toward testis, in particular following the identification in 1990 of the SRY factor on chromosome Y. The mechanisms involved in gonad differentiation toward ovary took longer to identify. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.04.004DOI Listing

What do you need to know about mass spectrometry? A brief guide for endocrinologists.

Ann Endocrinol (Paris) 2020 Jun 11;81(2-3):118-123. Epub 2020 Apr 11.

Laboratoire d'hormonologie, hôpital Haut-Lévêque, CHU de Bordeaux, 33604 Pessac, France; Nutrition et neurobiologie intégrée, UMR 1286, université de Bordeaux, 33076 Bordeaux, France; Groupe de biologie spécialisée, societé française de medecine nucléaire, 5, rue Ponscarme 75013, Paris, France. Electronic address:

In routine hormonology, liquid chromatography mass spectrometry (LCMS) is now an established technique for androgen, urinary cortisol and metanephrine assay. It has the undeniable advantage of great analytical specificity, but with sensitivity that clearly depends on financial investment in a very high-end spectrometer. We describe the general principles of LCMS and the routine applications so far developed in hormonology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.021DOI Listing

Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.

Ann Endocrinol (Paris) 2020 Jun 10;81(2-3):78-82. Epub 2020 Apr 10.

Servicio de Endocrinología y de la Clínica de Enfermedades Crónicas de la Unidad de Especialidades Médicas, 53960 Edo Mex, MX.

Purpose: To describe pre- to post-treatment changes in clinical activity score (CAS) and exophthalmometry in patients with Graves orbitopathy treated with tocilizumab (TCZ).

Material And Methods: Eight Mexican patients presenting with active Graves orbitopathy (CAS>3/7) previously treated with glucocorticoids received 1 monthly dose of TCZ for 6 months. CAS, EUGOGO severity assessment and exophthalmometry were used to evaluate clinical status, with serum measurement of thyroid-stimulating hormone receptor antibodies (TR-Ab) for biochemical evaluation before and after application of TCZ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.01.003DOI Listing

"Is there any reason to treat subclinical hypo and hyperthyroidism?"

Ann Endocrinol (Paris) 2020 Mar 4. Epub 2020 Mar 4.

University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy. Electronic address:

Subclinical thyroid disease represents an early stage of thyroid dysfunction, which is usually asymptomatic and biochemically defined; its diagnosis can be performed thanks to the high sensitivity of the hypothalamic-pituitary-thyroid axis. The approach to this disorder requires correct diagnosis, clinical assessment and treatment. Cardiovascular diseases (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.003DOI Listing

Cardiovascular complications of lipodystrophic syndromes - focus on laminopathies.

Ann Endocrinol (Paris) 2020 Mar 4. Epub 2020 Mar 4.

Centre national de Référence des Pathologies Rares de l'Insulino- Sécrétion et de l'Insulino -Sensibilité (PRISIS), Service d'Endocrinologie, Diabétologie et Endocrinologie de la Reproduction, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France; Sorbonne Université, Inserm UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France; Laboratoire Commun de Biologie et Génétique Moléculaires, Hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.002DOI Listing

Therapeutic applications of thyroid hormone analogues.

Authors:
W E Visser

Ann Endocrinol (Paris) 2020 Mar 4. Epub 2020 Mar 4.

Department of Internal Medicine, Rotterdam Thyroid Centre, Erasmus Medical Centre, Rotterdam, Netherlands. Electronic address:

Cellular thyroid hormone homeostasis requires adequate function of: (1) thyroid hormone transporter proteins at the plasma membrane, (2) deiodinating enzymes and (3) nuclear thyroid hormone receptors (TRs). Defects in any of these processes give rise to distinct disease entities, collectively called thyroid hormone signaling disorders. Thyroid hormone analogues hold therapeutic potential in thyroid hormone signaling disorders by bypassing defective transporters or binding to mutant TRs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.03.004DOI Listing

PTH and cardiovascular risk.

Authors:
Damien Gruson

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

Department of Clinical Biochemistry, cliniques universitaires Saint-Luc, université catholique de Louvain, Brussels, Belgium; Pôle de recherche en endocrinologie, diabète et nutrition, institut de recherche expérimentale et clinique, cliniques universitaires Saint-Luc, université catholique de Louvain, Brussels, Belgium. Electronic address:

Cardiovascular diseases remain the leading cause of non-communicable chronic diseases, are related to high morbidity and mortality and are associated to a huge impact on healthcare budgets. Biomarkers play an important role for the diagnosis and prognosis of cardiovascular diseases and are recognized tools for value-based care. Parathyroid hormone (PTH) is a major systemic calcium-regulating hormone and an important regulator of bone and mineral homeostasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.005DOI Listing
February 2020

Cardiovascular consequences of parathyroid disorders in adults.

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

Department of Clinical Medicine, Aarhus University, Aarhus University Hospital, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

PTH is a metabolic active hormone primarily regulating calcium and phosphate homeostasis in a very tight and short term-manner. Parathyroid disorders in adult patients reflect a variety of different conditions related either to the parathyroid glands itself or to the effects of the secreted hormone. The clinical spectrum varies from the common disease primary hyperparathyroidism (PHPT) to the orphan conditions pseudohypoparathyroidism (Ps-HypoPT) and chronic hypoparathyroidism (HypoPT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.003DOI Listing
February 2020

The cardiovascular consequences of hyperaldosteronism.

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

Hypertension Unit, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Primary aldosteronism (PA), the most common form of secondary hypertension, has been considered for decades as a "benign" form of hypertension, but evidences progressively built up to show that patients with PA had an excess rate of cardiovascular damage as compared to blood pressure-matched essential hypertensive patients. This review provides an updated view of structural and electrical cardiac remodeling and of vascular changes in hyperaldosteronism, and how they can favor development of cardiovascular events. The link between hyperaldosteronism and resistant hypertension is also examined, and the impact of targeted treatment of hyperaldosteronism on cardiovascular changes is finally discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.006DOI Listing
February 2020

Cardiac gluco- and mineralocorticoid receptors: From development to pathology.

Authors:
Karen Chapman

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

University/BHF Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.004DOI Listing
February 2020

Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia.

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

Department of Endocrinology, Queen Mary University of London, E1 4NS London, United Kingdom; Department of Endocrinology, Saint-Bartholomew's Hospital, EC1A 7BE London, United Kingdom.

The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is controversial. As more evidence has emerged that the risks of cardiac valvulopathy in this population of patients are low, fewer and fewer endocrinologists adhere strictly to the original medicines and healthcare products agency MHRA guidance of "at least" annual echocardiography. Strict adherence to this guidance would be costly in monetary terms (£5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.007DOI Listing
February 2020

Thyroid hormone and mammalian tissue regeneration.

Ann Endocrinol (Paris) 2020 Feb 28. Epub 2020 Feb 28.

INRA USC 1370, institut de génomique fonctionnelle de Lyon, université de Lyon, Université Lyon, Lyon, France; 1, CNRS UMR 5242, école normale supérieure de Lyon, Lyon, France. Electronic address:

Recent articles show that thyroid hormone is a key determinant of regeneration. The regeneration capacity in adults of two cell types, cerebellum neurons and cardiomyocytes, disappeared during mammalian evolution. However, it persists at early stages of development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.002DOI Listing
February 2020

Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.

Ann Endocrinol (Paris) 2020 Feb 29. Epub 2020 Feb 29.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: Male hypogonadism, arising from a range of etiologies including androgen-deprivation therapies (ADTs), has been reported as a risk factor for acquired long-QT syndrome (aLQTS) and torsades de pointes (TdP). A full description of the clinical features of aLQTS associated with ADT and of underlying mechanisms is lacking.

Methods: We searched the international pharmacovigilance database VigiBase for men (n=6 560 565 individual case safety reports) presenting with aLQTS, TdP, or sudden death associated with ADT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.02.008DOI Listing
February 2020

Several critical genes and microRNAs associated with the development of polycystic ovary syndrome.

Ann Endocrinol (Paris) 2020 Feb 11;81(1):18-27. Epub 2019 Nov 11.

Department of Reproductive Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Electronic address:

Background: We aimed to identify key genes and microRNAs (miRNAs) associated with the development of polycystic ovary syndrome (PCOS).

Methods: GSE84376 mRNA microarray data (15 PCOS granulosa cells and 13 control granulosa cells) and GSE34526 mRNA microarray data (7 PCOS granulosa cells and 3 control granulosa cells) were downloaded from the Gene Expression Omnibus (GEO) database. First, differentially expressed gene (DEG) analysis, gene set enrichment analysis (GSEA) for differentially expressed mRNAs, and protein-protein interaction (PPI) network analysis were conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.10.002DOI Listing
February 2020
0.664 Impact Factor

Improvement in arterial stiffness (pOpmètre®) after bariatric surgery. Results from a prospective study.

Ann Endocrinol (Paris) 2020 Feb 1;81(1):44-50. Epub 2020 Feb 1.

Chirugie cancérologique digestive et endocrinienne (CCDE), institut des maladies de l'appareil digestif (IMAD), CHU de Nantes-Hôtel Dieu, Nantes, France; Inserm, CNRS, l'institut du thorax, Université Nantes, Nantes, France. Electronic address:

Background: Arterial stiffness (AS) is an independent predictor of cardiovascular risk, and could be used as a surrogate marker of improvement in cardiovascular risk following bariatric surgery. The aim of this study was to compare AS before and after surgery.

Methods: One hundred and thirty-four patients undergoing bariatric surgery between May 2016 and January 2019 were prospectively included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.01.002DOI Listing
February 2020

Ultrasound and cytological characteristics of non-invasive follicular thyroid neoplasm with papillary-like nuclear features compared to papillary carcinomas.

Ann Endocrinol (Paris) 2020 Feb 25;81(1):28-33. Epub 2020 Jan 25.

Service d'endocrinologie diabétologie et nutrition, CHRU Nancy, 54511 Vandœuvre-lès-Nancy, France. Electronic address:

Introduction: NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features, formerly non-invasive encapsulated follicular variant of papillary thyroid carcinoma) has been removed from the carcinoma category because of its indolent character and good prognosis. This change impacts clinical and surgical management, since these tumors no longer require total thyroidectomy, or complementary radioactive iodine therapy for <4cm tumor. The aim of the present study was to identify preoperative ultrasound and cytological differences between NIFTP and papillary thyroid carcinoma (PTC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.10.004DOI Listing
February 2020

Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma/paraganglioma: retrospective single-center study.

Ann Endocrinol (Paris) 2020 Feb 25;81(1):3-10. Epub 2020 Jan 25.

USHATE Academy Ivan-Penchev, Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.

Background: Carbohydrate disorders are the most frequent metabolic disorders, affecting a significant proportion of patients with pheochromocytoma.

Objective: A retrospective study assessed the prevalence and progression of carbohydrate disorders in 204 patients (92 men, 112 women) with histologically proven pheochromocytoma diagnosed in a single specialized tertiary center during a 40-year period (1978-2017). One hundred were followed-up after tumor removal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2020.01.001DOI Listing
February 2020

Long-term progression of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A single-center retrospective study of the French Marne-Ardennes thyroid cancer registry.

Ann Endocrinol (Paris) 2020 Feb 25;81(1):34-38. Epub 2020 Jan 25.

Nuclear medicine-thyroid Unit, Institut Godinot, 1, rue du Général-Koenig, 51100 Reims, France; Thyroid Cancer Registry of Marne-Ardennes, Institut Godinot, 1, rue du Général-Koenig, 51100 Reims, France.

Context: Non-invasive forms of encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) were reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in order to reduce overtreatment. A few studies showed neck lymphadenopathy at diagnosis, or even distant metastasis in patients with NIFTP.

Objective: Our aim was to report the frequency, clinical features and long-term progression of histologically confirmed NIFTP, using data from the French Marne-Ardennes thyroid cancer registry, and to compare findings against FVPTC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.12.001DOI Listing
February 2020

Fluctuation analysis of postoperative secretory status in patients operated for acromegaly.

Ann Endocrinol (Paris) 2020 Feb 19;81(1):11-17. Epub 2019 Dec 19.

Neurosurgery department, CHU Timone, Aix-Marseille university, AP-HM, Marseille, France; Inserm, MMG, Aix-Marseille university, Marseille, France.

Objective: The aim of this study was to describe endocrinological outcome in patients operated on for acromegaly.

Methods: A retrospective study included 167 patients. Patients were assessed in the early postoperative period (EPP), at 3 months (M3), at 1 year (Y1), and then annually. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.11.002DOI Listing
February 2020

Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.

Ann Endocrinol (Paris) 2020 Feb 16;81(1):39-43. Epub 2019 Dec 16.

Inserm U1251, service d'endocrinologie, Marseille Medical Genetics, Hôpital de la Conception, Aix-Marseille Université, AP-HM, Marseille, France. Electronic address:

Context: Pancreatic neuroendocrine tumors (PNETs) occur in more than 80% of patients with multiple endocrine neoplasia type 1 (MEN1) syndrome, with predominance of small (<1cm) non-functioning tumors, followed by gastrinomas and insulinomas. Due to their small size, the diagnostic performance of conventional MRI and CT imaging is highly variable, with a real risk of false-negatives. Functional imaging on 111In-DTPA-Octreotide SPECT somatostatin receptor scintigraphy (Octreoscan®) is the modality of choice, but shows only 80% sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.11.001DOI Listing
February 2020

Lipodystrophic syndromes: From diagnosis to treatment.

Ann Endocrinol (Paris) 2020 Feb 16;81(1):51-60. Epub 2019 Dec 16.

Sorbonne Université, Inserm UMR_S 938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Endocrinologie, Diabétologie et Endocrinologie de la reproduction, Centre national de Référence des Pathologies Rares de l'Insulino - Sécrétion et de l'Insulino-Sensibilité (PRISIS), Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Laboratoire Commun de Biologie et Génétique Moléculaires, Paris, France. Electronic address:

Lipodystrophic syndromes are acquired or genetic rare diseases, characterised by a generalised or partial lack of adipose tissue leading to metabolic alterations linked to strong insulin resistance. They encompass a variety of clinical entities due to primary defects in adipose differentiation, in the structure and/or regulation of the adipocyte lipid droplet, or due to immune-inflammatory aggressions, chromatin deregulations and/or mitochondrial dysfunctions affecting adipose tissue. Diagnosis is based on clinical examination, pathological context and comorbidities, and on results of metabolic investigations and genetic analyses, which together determine management and genetic counselling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.10.003DOI Listing
February 2020

Independent association of vitamin D and insulin resistance in obstructive sleep apnea.

Ann Endocrinol (Paris) 2019 Nov 1;80(5-6):319-323. Epub 2019 Nov 1.

Sleep Medicine Center, Nanfang Hospital, Southern Medical University, China. Electronic address:

Background: Vitamin D insufficiency and/or high levels of parathyroid hormone (PTH) seem to be associated with abnormal glucose metabolism, which is frequent in obstructive sleep apnea (OSA). The purpose of this study was to investigate vitamin D and PTH concentrations in OSA, and to explore potential links between vitamin D, PTH and insulin resistance (IR).

Methods: A total of 112 subjects with suspected OSA were recruited consecutively, and evaluated by polysomnography (PSG) to determine the number of apnea and hypopnea episodes per hour of sleep (apnea/hypopnea index: AHI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.09.004DOI Listing
November 2019
4 Reads

Can incomplete adrenal venous sampling data be used in predicting the subtype of primary aldosteronism?

Ann Endocrinol (Paris) 2019 Nov 18;80(5-6):301-307. Epub 2019 Oct 18.

Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Guo xue xiang, 37, Cheng Du, 610000 Sichuan, PR China. Electronic address:

Background: Adrenal venous sampling (AVS) is the gold standard for preoperative differentiation between unilateral and bilateral primary aldosteronism (PA). However, results are sometimes vitiated by failing to access the right adrenal vein.

Materials And Methods: The present study assumed that clinical decisions can be made with incomplete AVS data, by comparing aldosterone/cortisol (A/C) ratio in both left and right adrenal veins with that in the inferior vena cava (LAV/IVC and RAV/IVC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.10.001DOI Listing
November 2019

Adrenocortical carcinoma: Impact of surgical treatment.

Ann Endocrinol (Paris) 2019 Nov 18;80(5-6):308-313. Epub 2019 Oct 18.

Service de chirurgie viscérale et endocrinienne, CHU d'Angers, rue Larrey, 49933 Angers cedex 9, France.

Compared to benign adrenal lesions, secreting or otherwise, malignant adrenocortical carcinoma is rare. Overall prognosis is poor, with <50% 5-year survival. Various prognostic factors have been identified, some tumor-related and others directly linked to surgical treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.09.001DOI Listing
November 2019

When Graves' disease resists to surgery: A rare case of an association with follicular thyroid cancer in struma ovarii.

Ann Endocrinol (Paris) 2019 Nov 18;80(5-6):329-331. Epub 2019 Oct 18.

Department of nuclear medicine, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France; Inserm, UMR970, Paris-Cardiovascular Research Center, 75015 Paris, France; GRC n(o) 16, GRC tumeurs thyroïdiennes, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.09.002DOI Listing
November 2019

Metallothionein protein and minichromosome maintenance protein-2 expression in adrenocortical tumors.

Ann Endocrinol (Paris) 2019 Nov 18;80(5-6):324-328. Epub 2019 Oct 18.

Pathology department, Bnai-Zion Medical Center, Haifa, Israel.

Aim: Some resected adrenal-confined adrenocortical carcinomas metastasize and others not. The present study was designed to evaluate the expression of metallothionein protein (MT) and minichromosome maintenance protein-2 (MCM2) in adrenocortical carcinomas and adrenocortical adenomas, and to test the correlation between this and adrenocortical carcinoma aggressiveness.

Materials And Methods: The study comprised 14 patients operated on for adrenocortical carcinoma, 15 operated on for adrenocortical adenoma and 2 with normal adrenals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.09.003DOI Listing
November 2019

TSH inhibits eNOS expression in HMEC-1 cells through the TSHR/PI3K/AKT signaling pathway.

Ann Endocrinol (Paris) 2019 Nov 26;80(5-6):273-279. Epub 2019 Jul 26.

Department of Endocrinology 1, Affiliated Hospital of Jining Medical University, 272029 Jining, Shandong, China. Electronic address:

Objective: To investigate the effects of thyroid-stimulating hormone (TSH) on the expression of endothelial nitric oxide synthase (eNOS) in human microvascular endothelial cells (HMEC-1) and explore the potential mechanism.

Materials And Methods: Expression of thyroid-stimulating hormone receptor (TSHR) in HMEC-1 cells was determined by immunofluorescence, reverse transcription-polymerase chain reaction (RT-PCR), and Western blotting. Cell proliferation and the production of nitric oxide (NO) and superoxide anion (SA) were measured after TSH treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.06.007DOI Listing
November 2019

Proteomic analysis of the papillary thyroid microcarcinoma.

Ann Endocrinol (Paris) 2019 Nov 16;80(5-6):293-300. Epub 2019 Feb 16.

Department of General Surgery, Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot, China. Electronic address:

Objective: The present study applied iTRAQ and LC-MS/MS techniques for proteome analysis and compared data between specimens of papillary thyroid microcarcinoma (PTMC) vs appropriate controls, in order to investigate the mechanisms underlying the invasion and metastasis process in PTMC development.

Materials And Methods: Fresh-tissue specimens were collected from 40 patients with thyroid disease who underwent surgical treatment. Specimens were divided into four groups: normal histology (NH; n=8), benign thyroid tumor (BTT; n=10), classic PTMC with lymph node metastasis (PTC-LNM; n=11), and classic PTMC without lymph node metastasis (PTC-LNM; n=11). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.01.003DOI Listing
November 2019
1 Read

Weight-loss with activation of brown fat: Suspect pheochromocytoma.

Ann Endocrinol (Paris) 2019 Nov 26;80(5-6):314-318. Epub 2019 Jul 26.

Service d'endocrinologie et maladies métaboliques, hôpital Larrey, 24, chemin de Pouvourville, 31059 Toulouse cedex 9, France; Institut Cardiomet, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, 31400 Toulouse, France. Electronic address:

Introduction: Excess catecholamine stimulates heat production in brown adipose tissue (BAT). Activation of BAT can be detected in patients presenting pheochromocytoma.

Case Study: A 58-year-old female patient sought medical advice due to 13 kg weight loss over 2 years accompanied by sweating and high blood pressure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.06.004DOI Listing
November 2019
1 Read

Le syndrome des ovaires polykystiques : quelles nouveautés en 2019 ?: Keeping up with PCOS in 2019.

Ann Endocrinol (Paris) 2019 Sep;80 Suppl 1:S29-S37

Endocrinologie et métabolismes, CHU de Caen, Caen, France.

PolyCystic Ovary Syndrome (PCOS) is the first endocrinopathy of women of child-bearing age and the leading cause of anovulatory infertility. The pathophysiology of this syndrome is complex and involves genetic traits highlighted by GWAS and epigenetic traits with DNA methylation modifications. Initially described as an ovarian disease, works carried out over recent years were turned towards neuroendocrine disorder involving GABAergic pathways, KNDy neurons and a possible role of prenatal androgen exposure determined by animal models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(19)30114-3DOI Listing
September 2019
1 Read

La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019: Multiple Endocrine Neoplasia Type 1: Development after the ENETS 2019 Congress.

Ann Endocrinol (Paris) 2019 Sep;80 Suppl 1:S19-S28

Service endocrinologie et maladies métaboliques, pôle cardio-vasculaire et métabolique, CHU Larrey-Rangueil, Toulouse, France.

Multiple Endocrine Neoplasia Type 1 (NEM1) is related to mutations of the menin gene. It is an autosomal dominant disease. Its prevalence is about 1/30 000 with a hugh penetrance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(19)30113-1DOI Listing
September 2019
1 Read

Acromégalie : améliorer la prise en charge: Acromegaly: improving care.

Ann Endocrinol (Paris) 2019 Sep;80 Suppl 1:S10-S18

Assistance publique-Hôpitaux de Paris, hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France; Faculté de médecine Paris-Sud, université Paris-Sud et Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.

Acromegaly is characterized by increased release of growth hormone (GH) and, consequently, Insulin-Like Growth Factor I (IGF-I), most often by a pituitary adenoma. Prolonged exposure to excess hormone leads to progressive somatic disfigurement and a wide range of systemic manifestations that are associated with increased mortality. Transsphenoidal adenomectomy is the treatment of choice of GH-secreting pituitary tumors but surgical cure is not achieved in around 50% of patients, then adjuvant treatment is necessary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(19)30112-XDOI Listing
September 2019
1 Read

Insuffisance surrénalienne secondaire : actualités diagnostiques et thérapeutiques: News in diagnosis and therapeutics of secondary adrenal insufficiency.

Ann Endocrinol (Paris) 2019 Sep;80 Suppl 1:S1-S9

Service d'endocrinologie, diabétologie et nutrition, CHU Bordeaux, hôpital Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France. Electronic address:

Immunotherapy and opioids treatment are new causes of secondary adrenal insufficiency (SAI). Prevalence of SAI with immunotherapy is more frequent with combined therapy (8% vs 4 to 10% with CTLA4 blocking antibody and 1% with PD1 blocking antibody). Although hypophysitis are more frequently observed with CTLA4 blocking antibody, some cases of Isolated SAI have been reported in patients treated by PD1 blocking antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(19)30111-8DOI Listing
September 2019
7 Reads